Article
Plant Sciences
Gakyung Lee, Jinyoung Park, Hyunbeom Lee, Kyeong Seok Kim, Jae Hyeon Park, So Young Kyung, Hyung Sik Kim, Hyun Ok Yang, Byung Hwa Jung
Summary: This study evaluated the therapeutic effects of BS012 on AD and investigated the underlying metabolic mechanisms. Results showed that BS012 exerted strong anti-atopic activity by reducing Th2-specific inflammatory response and improving skin barrier function. This novel combination could be a potential alternative for AD treatment and provide crucial information for the development of natural products.
Article
Pharmacology & Pharmacy
Pei-Yi Sun, Hua-Guo Li, Qian-Yue Xu, Zhen Zhang, Jia-Wen Chen, Yi-Hang Shen, Xin Qi, Jian-Fei Lu, Yi-Dong Tan, Xiao-Xiao Wang, Chun-Xiao Li, Meng-Ying Yang, Yu-Zhi Ma, Ying Lu, Tian-Le Xu, Jin-Wen Shen, Wei-Guang Li, Yi-Feng Guo, Zhi-Rong Yao
Summary: This study found that lidocaine can alleviate itch and skin lesions in atopic dermatitis by blocking certain subpopulations of sensory neurons. It also suggests that lidocaine may be a potential treatment for atopic dermatitis.
BRITISH JOURNAL OF PHARMACOLOGY
(2023)
Article
Medicine, General & Internal
Trinidad Montero-Vilchez, Juan-Angel Rodriguez-Pozo, Pablo Diaz-Calvillo, Maria Salazar-Nievas, Jesus Tercedor-Sanchez, Alejandro Molina-Leyva, Salvador Arias-Santiago
Summary: The study aimed to evaluate the impact of dupilumab on skin barrier function in patients with atopic dermatitis (AD) and compare it with other treatments. The study found that dupilumab was more effective in improving barrier function in both eczematous lesions and non-lesioned skin compared to topical corticosteroids and cyclosporine.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Veterinary Sciences
Jihee Kim, Ji-Hye Lee, Yunji Song, Ha-Jung Kim
Summary: This study analyzed the correlation between indoor house dust mite (HDM) concentration, canine atopic dermatitis (CAD) severity, and residential environments in 35 CAD dogs and 13 healthy dogs. The results showed that Der f 1 concentration had a negative association with transepidermal water loss (TEWL), but no association with CAD severity index-04 (CADESI-04) and pruritus visual analog scale (PVAS). Der f 1 concentration was significantly higher in the group living near green areas and with indoor relative humidity (RH) ≥40%. The study suggests that living near green areas and maintaining appropriate indoor climate may improve CAD clinical symptoms, and high concentrations of HDM may enhance the skin barrier function.
FRONTIERS IN VETERINARY SCIENCE
(2023)
Article
Pharmacology & Pharmacy
Silvia Ferrucci, Maurizio Romagnuolo, Carlo Alberto Maronese, Francesca Germiniasi, Simona Tavecchio, Luisa Angileri, Giovanni Casazza, Angelo Valerio Marzano, Giovanni Genovese
Summary: The study aimed to assess skin barrier status in nonlesional skin of severe AD patients treated with dupilumab, by evaluating the association between TEWL variation and EASI75 achievement over time. During dupilumab treatment, TEWL on nonlesional skin tends to significantly improve 4 months after treatment initiation, serving as a useful tool for monitoring therapy response.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE
(2021)
Article
Dermatology
Yixin Shao, Yiqi Zhu, Zijing Xiao, Yanyun Shen, Beiying Dai, Hui Tang, Duoqin Wang
Summary: This study explored the cutaneous transcriptome of atopic prurigo nodularis (APN) with severe pruritus and compared it with classic atopic dermatitis (AD). The findings revealed that both diseases showed increased expression levels of itch/inflammation-related genes, but APN had mainly elevated levels of neuroactive molecules, while AD showed increased levels of inflammatory mediators. Both disorders exhibited mixed Th1/Th2/Th17 polarization and impaired skin barrier. Unique features of APN included M1/M2 macrophage activation, tumor necrosis factor production, fibrosis, revascularization, and neural dysregulation.
EXPERIMENTAL DERMATOLOGY
(2023)
Article
Medicine, General & Internal
Trinidad Montero-Vilchez, Maria-Victoria Segura-Fernandez-Nogueras, Isabel Perez-Rodriguez, Miguel Soler-Gongora, Antonio Martinez-Lopez, Ana Fernandez-Gonzalez, Alejandro Molina-Leyva, Salvador Arias-Santiago
Summary: This study compared skin barrier function between healthy skin, psoriatic skin, and atopic dermatitis skin, finding that TEWL was higher at psoriatic and AD lesions, while SCH was lower. Specific TEWL and temperature values may help clinicians determine disease severity and treatment needs.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Pharmacology & Pharmacy
Yubin Xu, Saizhen Chen, Lingling Zhang, Guirong Chen, Jinguang Chen
Summary: The study indicates that Huanglian Jiedu decoction can treat atopic dermatitis by regulating the antigen presentation function of dendritic cells, weakening T-lymphocyte activation, and subsequently exerting anti-inflammatory and anti-pruritus effects.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Dermatology
Madeline Kim, Ester Del Duca, Julia Cheng, Britta Carroll, Paola Facheris, Yeriel Estrada, Amy Cha, John Werth, Robert Bissonnette, Karl Nocka, Chuanbo Zang, Ana B. Pavel, Emma Guttman-Yassky
Summary: This study investigates the mechanism of action of 2% crisaborole ointment, a topical nonsteroidal PDE4 inhibitor, demonstrating its ability to reverse dysregulation in the proteome of patients with mild to moderate atopic dermatitis (AD) and impact key markers and pathways associated with AD pathogenesis. These findings provide further support for crisaborole and topical PDE4 inhibition in the treatment of mild to moderate AD.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2023)
Article
Food Science & Technology
Emilia Alves, Joao Gregorio, Andre Rolim Baby, Patricia Rijo, Luis M. Rodrigues, Catarina Rosado
Summary: Diet plays a fundamental role in maintaining the balance of bodily functions, including skin health, through the gut-skin axis. Probiotics in kefir have potential therapeutic benefits for inflammatory skin diseases like atopic dermatitis. The intake of homemade kefir has been shown to improve skin barrier function and severity of atopic dermatitis, particularly in terms of skin hydration.
Article
Cell Biology
Na-Hee Jeong, Soyoung Lee, Young-Ae Choi, Kyung-Sik Song, Sang-Hyun Kim
Summary: Atopic dermatitis (AD) is a complex skin disease characterized by inflammation and intense itching, with limited effective treatments and potential side effects. Euscaphic acid, derived from natural products, shows anti-inflammatory, anticoagulant, and antioxidant effects in experimental models. It effectively ameliorated AD properties in mouse models by reducing inflammatory cytokines, pruritus factors, and mast cell invasion, suggesting its potential as a therapeutic agent for AD.
Review
Medicine, General & Internal
Dimitra Koumaki, Stamatios Gregoriou, George Evangelou, Konstantinos Krasagakis
Summary: Atopic dermatitis (AD) is a common inflammatory skin disorder characterized by intense itchiness that affects both children and adults. This review analyzes the underlying causes of itchiness in AD, including histamine-dependent and histamine-independent pruritogens. Various mediators, such as substance P, secreted molecules, chemokines, and cytokines, are involved in chronic itch. Additionally, emerging antipruritic drugs for AD are summarized.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Allergy
Lena Mobus, Elke Rodriguez, Inken Harder, Dora Stolzl, Nicole Boraczynski, Sascha Gerdes, Andreas Kleinheinz, Susanne Abraham, Annice Heratizadeh, Christiane Handrick, Eva Haufe, Thomas Werfel, Jochen Schmitt, Stephan Weidinger
Summary: Skin transcriptome studies in atopic dermatitis have shown core features of disturbed epidermal differentiation and IL-31/IL-1 signaling activation, along with type 2 inflammation, T(H)17 signaling, and natural killer cell function. IL4RA is a key dysregulated gene, and cyclosporine and dupilumab have distinct effects on the transcriptome in AD patients.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Tobias Weihrauch, Maren M. Limberg, Natalie Gray, Martin Schmelz, Ulrike Raap
Summary: Allergic diseases can cause various symptoms such as itching, coughing, sneezing, and watery eyes, leading to severe physiological and psychological impairments. The mechanisms of these conditions are still not fully understood, but recent studies have shown the high relevance of neurotrophins in allergic inflammation. Neurotrophins induce cytokine release, facilitate interactions between immune cells and neurons, and show different expression levels in health and disease. In this review, the role of neurotrophins in atopic disorders like atopic dermatitis, allergic asthma, and allergic rhinitis is discussed.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Dermatology
Melinda J. Gooderham, Giampiero Girolomoni, Julian O. Moore, Jonathan Silverberg, Robert Bissonnette, Seth Forman, Elena Peeva, Pinaki Biswas, Hernan Valdez, Gary Chan
Summary: This study suggests that 12 weeks of abrocitinib therapy is safe and effective for moderate-to-severe atopic dermatitis, and continuous use of abrocitinib can lead to better long-term outcomes.
DERMATOLOGY AND THERAPY
(2022)
Article
Allergy
Tali Czarnowicki, Helen He, Talia Canter, Joseph Han, Rachel Lefferdink, Taylor Erickson, Stephanie Rangel, Naoya Kameyama, Hyun Je Kim, Ana B. Pavel, Yeriel Estrada, James G. Krueger, Amy S. Paller, Emma Guttman-Yassky
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2020)
Article
Allergy
Benjamin Ungar, Ana B. Pavel, Randall Li, Grace Kimmel, John Nia, Peter Hashim, Hee Jin Kim, Margot Chima, Anjali S. Vekaria, Yeriel Estrada, Hui Xu, Xiangyu Peng, Giselle K. Singer, Danielle Baum, Yasaman Mansouri, Mark Taliercio, Emma Guttman-Yassky
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2021)
Article
Dermatology
Jacob W. Glickman, Celina Dubin, Yael Renert-Yuval, Dante Dahabreh, Grace W. Kimmel, Kelsey Auyeung, Yeriel D. Estrada, Giselle Singer, James G. Krueger, Ana B. Pavel, Emma Guttman-Yassky
Summary: This study identified abnormality in moderate to severe alopecia areata (AA) and associated circulatory biomarkers. The results show systemic immune, cardiovascular, and atherosclerosis biomarker dysregulation in AA patients, indicating the necessity for systemic treatment approaches.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2021)
Article
Allergy
Ana B. Pavel, Yael Renert-Yuval, Jianni Wu, Ester Del Duca, Aisleen Diaz, Rachel Lefferdink, Milie M. Fang, Talia Canter, Stephanie M. Rangel, Ning Zhang, James G. Krueger, Amy S. Paller, Emma Guttman-Yassky
Summary: Global transcriptomic profiling using tape strips in early-onset pediatric AD reveals immune and barrier alterations in both lesional and nonlesional skin, with significant dysregulation of Th2 and Th22/Th17-related genes. This approach provides insight into disease pathomechanisms and cutaneous disease activity, highlighting the potential utility of tape strips in studying pediatric AD.
Letter
Allergy
Ana B. Pavel, Jianni Wu, Yael Renert-Yuval, Ester Del Duca, Jacob W. Glickman, Rachel L. Miller, Amy S. Paller, James G. Krueger, Emma Guttman-Yassky
Article
Allergy
Helen He, Robert Bissonnette, Jianni Wu, Aisleen Diaz, Etienne Saint-Cyr Proulx, Catherine Maari, Carolyn Jack, Maudeline Louis, Yeriel Estrada, James G. Krueger, Ning Zhang, Ana B. Pavel, Emma Guttman-Yassky
Summary: This study utilized RNA-seq analysis of tape strips from lesional and nonlesional skin of patients with moderate-to-severe AD and psoriasis, revealing distinct immune and barrier signatures in the two diseases. The findings suggest the potential utility of tape strips as a minimally invasive alternative to biopsies for detecting disease biomarkers. Differences in gene expression profiles between AD and psoriasis highlight the unique pathophysiological mechanisms of these two skin disorders.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2021)
Article
Allergy
Helen He, Ester Del Duca, Aisleen Diaz, Hyun Je Kim, Jesus Gay-Mimbrera, Ning Zhang, Jianni Wu, Jessica Beaziz, Yeriel Estrada, James G. Krueger, Ana B. Pavel, Juan Ruano, Emma Guttman-Yassky
Summary: This study found that markers of epidermal hyperplasia and T-cell/dendritic cell infiltration were increased in the skin tissues of all AD patients, regardless of disease severity. Levels of T(H)2/T(H)22 cytokines were significantly elevated in both lesional and nonlesional skin of all patients, while T(H)1 and T(H)17 markers were increased only in lesional skin of mild AD patients. Blood profiles showed gradual increases in inflammatory markers in moderate and severe AD patients, but no significant differences were observed in mild AD patients compared to healthy controls.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2021)
Letter
Allergy
Caroline Meyer Olesen, Ana B. Pavel, Jianni Wu, Daniela Mikhaylov, Ester Del Duca, Yeriel Estrada, James G. Krueger, Ning Zhang, Maja-Lisa Clausen, Tove Agner, Emma Guttman-Yassky
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2021)
Letter
Allergy
Jacob W. Glickman, Ana B. Pavel, Emma Guttman-Yassky, Rachel L. Miller
Article
Dermatology
Paola Morelli, Marco Gaspari, Caterina Gabriele, Stefano Dastoli, Luigi Bennardo, Ana Brandusa Pavel, Cataldo Patruno, Ester Del Duca, Steven P. Nistico
Summary: The study investigated the proteomic profile of the skin barrier in atopic dermatitis (AD) patients, revealing various abnormalities including downregulation of proteins, lipid metabolism disturbances, imbalance of antioxidant and inflammatory processes, among others. This research offers a new perspective on the pathomechanisms of AD by identifying a unique signature in the skin barrier of AD patients.
EXPERIMENTAL DERMATOLOGY
(2021)
Editorial Material
Pharmacology & Pharmacy
Gerald R. Galluppi, Satjit Brar, Luzelena Caro, Yuan Chen, Nicolas Frey, Hans Peter Grimm, Deanne Jackson Rudd, Chi-Chung Li, Mindy Magee, Arnab Mukherjee, Lee Nagao, Vivek S. Purohit, Amit Roy, Ahmed Hamed Salem, Vikram Sinha, Ahmed A. Suleiman, Kunal S. Taskar, Vijay V. Upreti, Benjamin Weber, Jack Cook
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Pharmacology & Pharmacy
Yuet Mei Khong, Jing Liu, Jack Cook, Vivek Purohit, Karen Thompson, Shailly Mehrotra, S. Y. Amy Cheung, Justin L. Hay, Elimika Pfuma Fletcher, Jian Wang, Hari Cheryl Sachs, Hao Zhu, Akhtar Siddiqui, Lea Cunningham, Arzu Selen
Summary: The workshop focused on advancing pediatric drug product development efforts through collaboration in various sectors. The clinical session highlighted the interconnection between pediatric formulation design, clinical development strategy, and pediatric clinical pharmacology. Collaborative strategic planning among stakeholders is essential for the success of pediatric drug product development, especially in the alignment between formulators and clinical pharmacology teams.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
(2021)
Article
Dermatology
Madeline Kim, Daniela Mikhaylov, Stephanie M. Rangel, Ana B. Pavel, Helen He, Yael Renert-Yuval, Ester Del Duca, Kunal Malik, Thy Huynh, Erin Ibler, Mary Sun, Ning Zhang, Yeriel Estrada, James Krueger, Amy S. Paller, Emma Guttman-Yassky
Summary: The study provides comprehensive characterization of skin from different subtypes of ichthyosis, revealing shared inflammatory and barrier function abnormalities. These findings contribute to the understanding of the pathogenesis of these subtypes and inform the development of subtype-specific treatments.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2022)
Article
Pharmacology & Pharmacy
Jian Liu, Rohit Solan, Robert Wolk, Anna Plotka, Melissa T. O'Gorman, Jennifer A. Winton, Julia Kaplan, Vivek S. Purohit
Summary: This study evaluated the impact of ritlecitinib on the pharmacokinetics of caffeine, a substrate of CYP1A2. The results showed that coadministration of ritlecitinib with caffeine increased the exposure of caffeine. Ritlecitinib is a moderate inhibitor of CYP1A2 and can increase systemic exposures of CYP1A2 substrates.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2023)
Article
Pharmacology & Pharmacy
Xiaoxing Wang, Vivek Purohit, Martin E. Dowty, David Rodrigues, Lina Luo, Sumathy Mathialagan, William Carey, Anna Plotka, Hindu Kalluru, O'Gorman Melissa, Julia Kaplan, Yeamin Huh, Manoli Vourvahis, Robert M. Wolk
Summary: Ritlecitinib has been developed as a potential treatment for inflammatory diseases and has been shown to inhibit OCT1, but not OCT2 or MATE1/2K, based on clinical interaction studies.
JOURNAL OF CLINICAL PHARMACOLOGY
(2023)